Gordon Foulkes

Company: Lipidio Pharmaceuticals

Job title: Chief Executive Officer

Bio:

Dr. Gordon Foulkes with over 30 years of experience in leading and investing in biopharmaceutical research and development companies, and a career which has spanned working with four Nobel Laurates. Dr Foulkes founded Lipidio Pharma in 2020. Dr Foulkes served as Executive Chairman of Redwood BioSciences from 2012 until its acquisition by Catalent. Redwood was formed based on technology licensed from Carolyn Bertozzi’s Lab. Previously, Dr. Foulkes served as the founding CEO of Excaliard Pharmaceuticals from 2007 to 2009 and resumed that role in 2010, to lead the acquisition of Excaliard by Pfizer in 2011. From 2005 to 2010, Dr. Foulkes served as Managing Director at RiverVest Ventures, where he represented the RiverVest’s investments in Mpex (acquired by Axcan in 2011), CGI Pharmaceuticals (acquired by Gilead in 2010), Cabrellis (acquired by Pharmion in 2007 (now Celgene)), Conforma (acquired by Biogen in 2006), Excaliard (acquired by Pfizer in 2011) and MacroGenics (which completed an initial public offering in 2013). Previously, he headed research and development, and served on the boards of multiple biotechnology companies, including OSI Pharmaceuticals (Nasdaq: OSIP) acquired by Astellas for $4 billion in 2010, Aurora Biosciences (Nasdaq: ABSC, founded by Roger Tsien) acquired by Vertex in 2001 for $590M and Elitra Pharmaceuticals (acquired by Merck). At OSI (founded by James Watson) he pioneered the early development of cell-based high-throughput drug screening and oversaw multiple drug discovery and development programs, including the discovery of the first approved kinase inhibitors (Tarceva an anti-cancer drug) and the discovery of TGF-β3. In operational executive management positions, he has had a lead role in securing more than 15 corporate partnerships, resulting in over $350 million in recognized revenues, as well as directly participating in raising ~$300 million in private offerings, initial public offerings and follow-on public offerings. Prior to joining the biopharmaceutical industry, Dr. Foulkes held academic positions at both the Massachusetts Institute of Technology (with Prof. David Baltimore) and the Medical Research Council (UK). Dr. Foulkes obtained a First-Class Honors BSc degree from the University of Wales and his Ph.D. with Prof. Sir Philip Cohen, from the University of Dundee, Scotland.

Seminars:

Targeting SCD1 to Harness the Skin as an Endocrine Organ for Sustainable Weight Loss to Redefine Obesity Care 11:30 am

Targeting SCD1 offers a novel mechanism to increase energy expenditure without elevating heart rate, which provides a well-tolerated and sustainable pathway for weight loss This unique approach to lipid metabolism provides the distinct advantage of preferential fat reduction while preserving lean muscle mass, resulting in significant improvements in body composition and metabolic health markers The…Read more

day: Pre-Conference Day